Home Overview Press Room Blog Publications For Students about us
Search

About California Policies & Human Biotechnology


California has been a pioneer in several aspects of policy on new biotechnologies, most notably with the passage in 2004 of Proposition 71, which established the California Institute for Regenerative Medicine (CIRM) and authorized to distribute and oversee $3 billion in public funds to support stem cell research and build research facilities over ten years.

The CIRM has been closely watched by other states and countries. It launched two experiments: the first an experiment in biomedical investigation; the second in its politics and policy. Never before has a state so generously funded an emerging scientific field. And never before has a state been faced with regulating and overseeing a field that combines promising medical research with significant social risks.

Before that, the California Advisory Committee on Human Cloning issued a report that led to a state ban on reproductive cloning. In 2003, a state agency blocked the sale of genetically modified fish as pets. In 2006, the state legislature passed a law providing protections for women who may provide eggs for cloning-based stem cell research.



California’s Stem Cell Agency “Stacks the Deck” at a Key Hearing by Marcy DarnovskyBiopolitical TimesJanuary 24th, 2012A meaningful review of the stem cell program by the Institute of Medicine could make an important contribution to needed changes at the agency.
Stacking the Deck on the Stem-Cell Programby Michael HiltzikLos Angeles TimesJanuary 21st, 2012The Institute of Medicine is poised to receive a one-sided picture of California's stem-cell program in their upcoming review.
A New Bay Area Lab Will Focus on Synthetic Biologyby Jeff Conant, Biopolitical Times guest contributorJanuary 19th, 2012Lawrence Berkeley National Laboratory, DOE, and UC Berkeley’s new Bay Area bio-lab is creeping into the news. But what’s the untold story?
Mercury News editorial: Stem-Cell Institute Should Take a Bow (Out)by Mercury News EditorialSan Jose Mercury NewsDecember 17th, 2011It would be wrong to ask for more public financing from California.
Ethics Concerns about Geron's Exit from the Stem Cell Businessby Pete ShanksBiopolitical TimesDecember 15th, 2011Some stem-cell scientists and bioethicists are critical of Geron's early termination of a clinical trial and willingness to include one last patient.
Hoping for Cures, Supporters May Back Another Ballot Measure for Stem Cell Agencyby Steve JohnsonSan Jose Mercury NewsDecember 8th, 2011California's $3 billion taxpayer-financed stem cell agency still has no treatments on the market and is now at a critical juncture that could determine how much longer it stays in operation.
Surrogacy Broker in “Baby-Selling Ring” Sent to Prison by Marcy DarnovskyBiopolitical TimesDecember 7th, 2011The first of three women who created an "inventory of babies" and sold them at high prices has been sentenced.
Lawyer in Baby-Selling Ring Sentencedby Greg MoranSign On San DiegoDecember 1st, 2011The first of three women who pleaded guilty to running an international baby-selling ring was sentenced Thursday to one year in custody by a federal judge.
Bay Area Local News Reports on Asian Egg Marketby Osagie ObasogieBiopolitical TimesNovember 17th, 2011Demand is high for young Asian women willing to provide their eggs for other people’s fertility treatment.
Geron Quits the Embryonic Stem Cell Industryby Pete ShanksBiopolitical TimesNovember 16th, 2011Geron has cancelled its clinical trial of a stem-cell treatment for spinal cord injuries, raising questions about the future of the company and the industry.
Displaying 1-10 of 594  
Next >> 
Last Page » 
« Show Complete List » 


ESPAÑOL | PORTUGUÊS | Русский

home | overview | blog | publications| about us | donate | newsletter | press room | privacy policy

CGS • 1936 University Ave, Suite 350, Berkeley, CA 94704 • • (p) 1.510.625.0819 • (F) 1.510.665.8760